We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| ALK Abello AS | TG:4AJ0 | Tradegate | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | |
|---|---|---|---|---|---|
| -0.18 | -0.83% | 21.56 | 21.46 | 21.66 |
| High Price | Low Price | Open Price | Shares Traded | Last Trade |
|---|---|---|---|---|
| 21.38 | 21.32 | 21.38 | 90 | 22:50:06 |
| Date | Time | Source | Headline |
|---|---|---|---|
| 20/12/2024 | 16:08 | UKREG | ALK – Financial calendar for the 2025 financial year |
| 18/12/2024 | 11:51 | UKREG | Positive results advance peanut tablet to phase II development |
| 12/12/2024 | 15:06 | UKREG | ACARIZAX® approved in Europe for treatment of young children |
| 27/11/2024 | 12:45 | UKREG | ALK’s pivotal phase 3 trial in children published in reputable scientific.. |
| 14/11/2024 | 06:30 | UKREG | Nine-month interim report (Q3) 2024 (unaudited) |
| 09/11/2024 | 22:29 | UKREG | ALK licenses rights to neffy®, the first approved adrenaline nasal spray.. |
| 07/11/2024 | 11:08 | UKREG | Invitation to the presentation of ALK’s results for the first nine months.. |
| 27/8/2024 | 15:30 | UKREG | Report on transactions with ALK-Abelló A/S B-shares and associated.. |
| 22/8/2024 | 15:49 | UKREG | Six-month interim report (Q2) 2024 |
| 22/8/2024 | 15:38 | UKREG | ALK upgrades its full-year revenue and earnings outlook |
1 Year ALK Abello AS Chart |
Intraday ALK Abello AS Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
